



**QUEEN'S
UNIVERSITY
BELFAST**

Porphyromonas pasteri and Prevotella nanceiensis in the sputum microbiota are associated with increased decline in lung function in individuals with cystic fibrosis

Webb, K., Zain, N. M. M., Stewart, I., Fogarty, A., Nash, E. F., Whitehouse, J. L., Smyth, A. R., Lilley, A. K., Knox, A., Williams, P., Cámara, M., Bruce, K., & Barr, H. L. (2022). Porphyromonas pasteri and Prevotella nanceiensis in the sputum microbiota are associated with increased decline in lung function in individuals with cystic fibrosis. *Journal of Medical Microbiology*, 71(2), Article 001481. <https://doi.org/10.1099/jmm.0.001481>

Published in:

Journal of Medical Microbiology

Document Version:

Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:

[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2023 the authors.

This is an open access article published under a Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: <http://go.qub.ac.uk/oa-feedback>

Porphyromonas pasteri and *Prevotella nanceiensis* in the sputum microbiota are associated with increased decline in lung function in individuals with cystic fibrosis

Karmel Webb^{1,2,*}, Nur Masirah M. Zain^{2,3,†}, Iain Stewart^{2,4}, Andrew Fogarty^{1,2}, Edward F. Nash⁵, Joanna L. Whitehouse⁵, Alan R. Smyth^{2,6}, Andrew K. Lilley³, Alan Knox^{2,4}, Paul Williams⁷, Miguel Cámara⁷, Kenneth Bruce^{2,3} and Helen L. Barr^{2,8}

Abstract

Although anaerobic bacteria exist in abundance in cystic fibrosis (CF) airways, their role in disease progression is poorly understood. We hypothesized that the presence and relative abundance of the most prevalent, live, anaerobic bacteria in sputum of adults with CF were associated with adverse clinical outcomes. This is the first study to prospectively investigate viable anaerobic bacteria present in the sputum microbiota and their relationship with long-term outcomes in adults with CF. We performed 16S rRNA analysis using a viability quantitative PCR technique on sputum samples obtained from a prospective cohort of 70 adults with CF and collected clinical data over an 8 year follow-up period. We examined the associations of the ten most abundant obligate anaerobic bacteria present in the sputum with annual rate of FEV₁ change. The presence of *Porphyromonas pasteri* and *Prevotella nanceiensis* were associated with a greater annual rate of FEV₁ change; -52.3 ml yr^{-1} (95% CI: -87.7 ; -16.9), -67.9 ml yr^{-1} (95% CI: -115.6 ; -20.1), respectively. Similarly, the relative abundance of these live organisms were associated with a greater annual rate of FEV₁ decline of -3.7 ml yr^{-1} (95% CI: -6.1 to -1.3 , $P=0.003$) and -5.3 ml yr^{-1} (95% CI: -8.7 to -1.9 , $P=0.002$) for each log₂ increment of abundance, respectively. The presence and relative abundance of certain anaerobes in the sputum of adults with CF are associated with a greater rate of long-term lung function decline. The pathogenicity of anaerobic bacteria in the CF airways should be confirmed with further longitudinal prospective studies with a larger cohort of participants.

INTRODUCTION

Chronic pulmonary infection and recurrent pulmonary exacerbations are associated with both increased morbidity and mortality in cystic fibrosis (CF) [1]. Historically, conventional microbiological culture techniques have routinely isolated several distinct aerobic species, such as *Staphylococcus aureus*, *Haemophilus influenzae* and *Pseudomonas aeruginosa*, which have been extensively studied [2].

However, conventional culture techniques only identify a very small proportion of the bacteria present in the lung environment. In recent years, culture-independent techniques such as PCR and microbiome analysis have shown that the CF airways are complex polymicrobial environments and often contain anaerobic bacteria [3–5], which are not routinely cultured in clinical practice.

The CF airways contain mucus, which adheres to epithelial surfaces. Within these mucus plugs, are biofilms with steep oxygen gradients, which are considered to be hypoxic environments, providing a niche for anaerobic bacteria [6, 7]. However, it is

Received 08 June 2021; Accepted 16 November 2021; Published 03 February 2022

Author affiliations: ¹Division of Epidemiology and Public Health, University of Nottingham, City Hospital Campus, Nottingham, UK; ²Nottingham NIHR Biomedical Research Centre, Nottingham MRC Molecular Pathology Node, UK; ³Institute of Pharmaceutical Science, King's College London, UK; ⁴Division of Respiratory Medicine, University of Nottingham, City Hospital Campus, Nottingham, UK; ⁵West Midlands Adult CF Centre, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; ⁶School of Medicine, University of Nottingham, Nottingham, UK; ⁷National Biofilms Innovation Centre, Biodiscovery Institute, School of Life Sciences, University of Nottingham, Nottingham, UK; ⁸Wolfson Cystic Fibrosis Centre, Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK.

***Correspondence:** Karmel Webb, karmel.webb1@nottingham.ac.uk

Keywords: cystic fibrosis; microbiology; anaerobic infection.

The raw sequence data reported in this study have been deposited in the European Nucleotide Archive under study accession number PRJEB4555.

†These authors contributed equally to this work

Three supplementary tables are available with the online version of this article.

001481 © 2022 The Authors



This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author's institution.

Table 1. Baseline clinical characteristics, summary of clinical data during the follow-up period and OTU abundance in each participant

Variable	Baseline (n=70)	
Age in years: median (range)	30.6 (17.8 to 61.5)	
Gender, males (%)	46 (65.1)	
FEV ₁ % predicted: mean (SD)	58 (±20)	
Absolute FEV ₁ in l: mean (SD)	2.2 (±0.9)	
BMI in kg m ⁻² : mean (SD)	22.9 (±3.4)	
<i>P. aeruginosa</i> status at baseline: n (%)		
Never	0 (0)	
Free	1 (1.4)	
Intermittent	1 (1.4)	
Chronic	68(97.1)	
Variable	N (%)	Outcome
Followup time* (years)	70 (100)	6.8 (6.2–8.1)
Number of lung transplantation	8 (11.4)	
Number of deaths	10 (14.2)	
Rate of lung function change per year†:		
Absolute FEV ₁ (ml)	68 (97)	–53.2 (±71.4)
Percent predicted FEV ₁ (%)	68 (97)	–1.4 (±1.9)
Variable per participant (n=70)	Range	Mean (SD)
Number of reads	9748–48 504	17 458.9 (±6306.1)
Number of OTUs	5–44	22.7 (±9.6)
Number of obligate anaerobe OTUs	0–17	6.3 (±4.4)
Total abundance, c.f.u. g ⁻¹ of sputum	5.0×10 ⁴ –3.9×10 ⁷	3.5×10 ⁶ (6.0×10 ⁶)
Obligate anaerobe abundance, c.f.u. g ⁻¹ of sputum	0–7.6×10 ⁶	6.1×10 ⁵ (1.3×10 ⁶)

n=number of participants with data available; SD=standard deviation, *P. aeruginosa* status of participants defined by Leeds criteria [17].

*Reported as median and interquartile range.

†Reported as mean and standard deviation.

currently not known whether these anaerobic bacteria play a pathophysiological role in lung damage, pulmonary exacerbations or long-term adverse outcomes in this patient population [6].

Sputum microbiome studies in CF have shown that the composition of bacterial communities remains relatively stable during exacerbations despite systemic antibiotic therapy [8, 9], and loss of species diversity is associated with reduced lung function [8, 10]. However, there are limited longitudinal data on the relationship between the sputum microbiome and long-term clinical outcomes [11]. Furthermore, whilst photoreactive dyes have been increasingly used to amplify and quantify only the bacterial cells with intact cell membranes in 16S rRNA sequencing [12], previous sputum microbiome studies in CF have not differentiated between viable and dead bacteria.

Using this viable cell technique, we investigated whether the presence and relative abundance of the ten most abundant, viable, obligate anaerobic bacterial species in CF sputum were associated with accelerated lung function decline in an 8 year follow up period.

METHODS

Participants and study design

We analysed sputum samples obtained adults with CF who had previously participated in a biomarker study (Research Ethics Committee; 09/H0407/1), the full details of which have been published [13]. In summary, participants were recruited at clinical




Fig. 1. Composition of (a) total obligate anaerobe OTUs within the viable CF total microbiome at clinical stability ($n=70$) and (b) individual OTUs included in the analysis within the total obligate anaerobe group ($n=65$).

stability from two UK adult CF centres between the years 2009 and 2011. Adults with CF were clinically stable at the study visit, having not experienced a pulmonary exacerbation requiring intravenous (IV) antibiotics in the preceding 4 weeks. Baseline demographic data were collected, and sputum plugs were stored for future microbiome analysis.

Clinical data

Lung function data were obtained from the UK CF registry [14] using the highest recorded forced expiratory volume in 1 s (FEV_1) of the preceding year. Annual data on lung function were collected from the participants from the year of recruitment to the end of the study period in 2017 or until year of death or lung transplantation.

Sample processing and microbiome analysis

Sputum plugs were harvested for microbiome analysis with an equal volume of 0.9% saline and stored in -80°C freezers. Prior to DNA extraction, known weight of sputum aliquots (up to 0.2 g) were pre-treated with propidium monoazide (PMA). PMA is

Table 2. Effect size of the presence relative to the absence and relative abundance of the ten most abundant obligate anaerobic species on annual rate of FEV₁ (ml) decline, N=68

Anaerobic species	N (%)	Coefficient (β) \pm	95% CI \pm	Coefficient (β)*	95% CI*
<i>Prevotella melaninogenica</i>	50 (73.5)	24.7	-13.6; 63.0	0.4	-2.0; 2.8
<i>Scardovia wiggisiae</i>	15 (22.1)	-7.6	-43.0; 27.8	-1.8	-4.1; 0.5
<i>Porphyromonas pasteri</i>	9 (13.2)	-52.3	-87.7; -16.9	-3.7	-6.1; -1.3
<i>Parvimonas micra</i>	7 (10.3)	6.5	-34.7; 47.7	-0.7	-4.1; 2.7
<i>Prevotella pallens</i>	20 (29.4)	14.4	56.5; 27.8	-0.7	-3.8; 2.4
<i>Stomatobaculum longum</i>	9 (13.2)	11.8	-38.6; 62.2	-0.7	-4.4; 2.8
<i>Fusobacterium nucleatum</i>	8 (11.8)	35.4	14.3; 85.2	2.3	-1.7; 6.2
<i>Prevotella nanceiensis</i>	31 (45.6)	-67.9	-115.6; -20.1	-5.3	-8.7; -1.9
<i>Prevotella oris</i>	14 (20.6)	-11.2	-64.2; 41.8	-1.0	-4.4; 2.4
<i>Atopobium rimae</i>	9 (13.2)	-22.6	-78.6; 33.4	-2.0	-5.5; 1.5

N: number of bacteria present in sputum of participants, β : coefficient of annualized rate of FEV₁ decline (ml yr⁻¹) \pm Effect size of annual rate of FEV₁ decline if bacterial species is present relative to absent, *: log₂ relative abundance and annual rate of FEV₁ decline, 95% CI; confidence intervals. 95% CI in bold are considered significant after Bonferroni correction (P=0.005).

unable to penetrate intact cell membranes and therefore only binds to the DNA of cells with compromised cell membranes [15]. Photo-activation of PMA results in covalent DNA modification and damage. This subsequently prevents amplification via PCR. Non-PMA treated matching sputum samples were used as positive controls.

DNA extraction was conducted using GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich, UK) according to the manufacturer's instructions, incorporated with additional enzymatic and physical disruption of samples. DNA was resuspended in 50 μ l of Elution Solution and quantified using a Picodrop Microlitre Spectrophotometer (GRI, UK). Phosphate-buffered solution was used as negative controls in DNA extraction and library preparation for sequencing and no amplification was detected above the lowest limit of detection (10 c.f.u. μ l⁻¹). Paired-end (300 bp) sequencing of 16S rRNA V3-V4 region for 75 DNA samples were then performed on the MiSeq platform (Illumina, USA). Sequence processing and analysis included quality filtering of reads, chimaera removal and assignment to Operational Taxonomic Units (OTUs) via the C9VLC pipeline and the QIIME software package (version 1.9.1, <http://qiime.org/>) (Eurofins, Germany).

Statistical analysis

Yearly change in lung function was predicted for each individual using linear regression models of CF registry-recorded FEV₁ values with their corresponding dates, and is reported as FEV₁ ml change per year (ml yr⁻¹).

The relative abundance of each OTU was initially expressed as a percentage (%) of the total number of reads in each individual. To allow comparison across the cohort, the % OTUs were transformed to c.f.u. (c.f.u. g⁻¹) of sputum by multiplying the % values with live total bacterial load in each sample accordingly, as informed by quantitative PCR (qPCR) [16]. The relative abundance (c.f.u. g⁻¹ of sputum) was subsequently transformed after the addition of 1 (log₂) for statistical analyses. The ten most abundant OTUs were determined by ranking the relative abundance of the OTUs present in all participants (Table S1, available in the online version of this article). Only the taxonomic level of species were included in the analyses. Generalized linear regression models were used to analyse the presence or absence and relative abundance (log₂) on the annual rate of FEV₁ change. Model fit was assessed using Akaike and Bayesian information criterion and both the dependant variable (FEV₁ decline) and model residuals were assessed and confirmed to be normally distributed.

All analyses were performed in Stata SE15 statistical software (Texas, USA), a P-value < 0.005 was considered statistically significant following Bonferroni correction for multiple comparison of ten OTUs.

RESULTS

Sputum samples and data were available for 70 (93.1%) of the 75 participants in the original study.

Sixty-eight (97.1%) of participants were chronically colonized with *P. aeruginosa* [17]. Baseline clinical characteristics and OTU abundance are summarized in Table 1.

A total of 1.2 million sequencing reads were obtained from the pooled sputum of each participant ($n=70$) and assigned to 212 OTUs. The assignment of 212 OTUs was determined by best-matching reference sequences to the most specific (lowest) taxonomic level. Within this dataset, 121 OTUs were classified as facultative anaerobes or aerobes, 73 OTUs as obligate anaerobes, while 18 OTUs assigned to taxa above genera were categorized as 'unclassified'. The lung microbiome for each CF individual varied from 5 to 44 different OTUs, with the highest richness of obligate anaerobes observed at 17 OTUs per participant (Table 1). Obligate anaerobes were present in 65/70 CF individuals, ranging from 0.1–70.6% of the total microbiome (Fig. 1). A list of OTUs and classification are presented in Tables S1 and S2. The ten most prevalent obligate anaerobes are summarized in Table S3.

Impact of the ten most abundant anaerobic species present in sputum on annual rate of FEV₁ change over an 8 year follow-up period

Two of the ten anaerobic species studied were associated with lung function decline: *Porphyromonas pasteri* and *Prevotella nanceiensis* (Table 2). The effect size of annual rate of FEV₁ decline if these viable organisms were present compared to absent was -52.3 ml yr^{-1} (95% CI: -87.7 to -16.9 , $P=0.004$) and -67.9 ml yr^{-1} (95% CI: -115.6 to -20.1 , $P=0.005$) (Table 2), respectively. Similarly, the relative abundance of live *P. pasteri* and *P. nanceiensis* was associated with a greater annual rate of FEV₁ decline of -3.7 ml yr^{-1} (95% CI: -6.1 to -1.3 , $P=0.003$) and -5.3 ml yr^{-1} (95% CI: -8.7 to -1.9 , $P=0.002$; Table 2) for each log₂ increment of abundance, respectively.

DISCUSSION

This is the first study to prospectively investigate viable anaerobic bacteria present in the sputum microbiota and relationship to long-term outcomes in adults with CF. The presence and relative abundance of both *Porphyromonas pasteri* and *Prevotella nanceiensis* in a cohort predominately colonized with *Pseudomonas aeruginosa* were associated with a greater annual lung function decline over the 8 year study period.

The lower airways in CF are polymicrobial and often contain anaerobes [3–5]. These anaerobes may be the result of repeated micro aspirations of oral flora in combination with an abnormal mucociliary clearance mechanism in CF airways [18], although not all data support this hypothesis [19–21]. For example, Rogers *et al.* demonstrated dissimilarity with paired expectorated sputum and mouthwash samples from the same CF individuals [22]. Despite the high abundance of anaerobes in the CF lower airways, their pathogenicity in the CF airways is not well understood. There is much deliberation over whether obligate anaerobic bacteria, such as *Prevotella* sp., which are known to be pathogenic and to harbour antimicrobial resistance genes [23], can also interact with other bacterial pathogens, such as *P. aeruginosa*, to enhance their virulence and growth [24, 25]. Indeed, evidence suggests *P. aeruginosa*, which preferably uses aerobic respiration, undergoes anaerobiosis in the presence of nitrate in the CF airways [26]. *Prevotella* species can protect *P. aeruginosa* against the activity of ceftazidime, an anti-pseudomonal antibiotic commonly used to treat pulmonary exacerbations [27]. Our data support these observations, suggesting that *Prevotella* sp. may be associated with adverse clinical outcomes. However, our observation that *Porphyromonas* was associated with adverse clinical outcomes is not supported by other studies. Studies in children with CF found that *Porphyromonas* sp. may protect against *P. aeruginosa* colonization [28, 29] and *Porphyromonas* sp. is also less abundant during pulmonary exacerbations, thus suggesting a protective role [28]. However, these studies were both performed in children without *P. aeruginosa*, while our study was performed in adults with chronic pulmonary *P. aeruginosa* and more severe pulmonary disease. We suggest that changes in community dynamics over time, spatial heterogeneity of the lungs and differing microenvironments may account for the contrasting observations. Zemanick *et al.* found that the presence of sputum anaerobes during a pulmonary exacerbation were associated with improved lung function and less inflammation [30], although there was significant variability in anaerobes in response to antibiotics (15). This suggests that diverse anaerobic species present in the airway may have distinct pathogenic or protective roles depending on individual interactions in the lung microbiota [11, 31].

Strengths of the study include the multicentre study population who were recruited from two adult specialist CF centres. Longitudinal follow up over an 8 year period provided robust linear modelling of lung function to predict FEV₁ outcomes. In addition, by using a novel PMA pre-treatment, we were able to give a more accurate estimate of viable anaerobic bacteria.

There are a number of limitations in this study that should be considered when interpreting these data. The enumeration of bacterial cells using the viability PCR technique has not been validated in comparison to standard culture methods for CF sputum [15]. Sputum samples were taken once at baseline only and compared with adverse clinical outcomes therefore findings should be considered as hypothesis generating. Whilst this offers novel insights, longitudinal profiling of the sputum microbiota (including aerobic and facultative anaerobic bacterial species) in a larger cohort and over multiple time points would aid our understanding further on the microbiological anaerobic community dynamics.

Our findings support a potential association of specific anaerobic species abundantly present in CF sputum with long-term lung function decline. These findings suggest that *Prevotella* and *Porphyromonas* species may contribute to lung disease and CF pathophysiology, which should be confirmed with a large, prospective cohort with regular microbiome profiling combined with enhanced validated sequencing strategies.

Funding information

Funding contributions from NIHR Nottingham Biomedical Research Centre and the U.K. Medical Research Council (grant no. G0801558/1). M.C. and P.W. are partly funded by The National Biofilms Innovation Centre (NBIC), which is an Innovation and Knowledge Centre funded by the Biotechnology and Biological Sciences Research Council, InnovateUK and Hartree Centre (Award No. BB/R012415/1).

Author contributions

K.W. and M.Z. are joint co-authors for this study. The study was designed by K.W., M.Z., H.B., A.F. and I.S. K.W. collected the clinical data, M.Z. and A.L. conducted the microbiome analysis. The statistical analysis was performed by K.W. and I.S. All authors contributed to data interpretation, data presentation and drafting of the manuscript. All authors approved the final version of the manuscript.

Conflicts of interest

The authors declare that there are no conflicts of interest.

References

1. Ellaffi M, Vinsonneau C, Coste J, Hubert D, Burgel P-R, et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. *Am J Respir Crit Care Med* 2005;171:158–164.
2. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, et al. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. *Ann Am Thorac Soc* 2014;11:1298–1306.
3. Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. *Curr Opin Pediatr* 2011;23:319–324.
4. Huang YJ, LiPuma JJ. The microbiome in cystic fibrosis. *Clin Chest Med* 2016;37:59–67.
5. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. *Am J Respir Crit Care Med* 2008;177:995–1001.
6. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, et al. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. *Ann Am Thorac Soc* 2014;11:1298–1306.
7. Mall MA, Danahay H, Boucher RC. Emerging concepts and therapies for mucoobstructive lung disease. *Ann Am Thorac Soc* 2018;15:S216–S226.
8. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. *PLoS One* 2012;7:e45001.
9. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. *Proc Natl Acad Sci U S A* 2012;109:5809–5814.
10. Carmody LA, Zhao J, Kalikin LM, LeBar W, Simon RH, et al. The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation. *Microbiome* 2015;3:12.
11. Jones AM. Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? *Thorax* 2011;66:558–559.
12. Nocker A, Sossa-Fernandez P, Burr MD, Camper AK, et al. Use of propidium monoazide for live/dead distinction in microbial ecology. *Appl Environ Microbiol* 2007;73:5111–5117.
13. Barr HL, Halliday N, Barrett DA, Williams P, Forrester DL, et al. Diagnostic and prognostic significance of systemic alkyl quinolones for *P. aeruginosa* in cystic fibrosis: A longitudinal study. *J Cyst Fibros* 2017;16:230–238.
14. UK Cystic Fibrosis Registry. <https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry>; (n.d.)
15. Rogers GB, Marsh P, Stressmann AF, Allen CE, Daniels TVW, et al. The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples. *Clin Microbiol Infect* 2010;16:1656–1658.
16. Rogers GB, Carroll MP, Zain NMM, Bruce KD, Lock K, et al. Complexity, temporal stability, and clinical correlates of airway bacterial community composition in primary ciliary dyskinesia. *J Clin Microbiol* 2013;51:4029–4035.
17. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM, et al. Evaluation of a new definition for chronic *Pseudomonas aeruginosa* infection in cystic fibrosis patients. *J Cyst Fibros* 2003;2:29–34.
18. Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, et al. Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children. *PLoS Pathog* 2018;14:e1006798.
19. Brown PS, Pope CE, Marsh RL, Qin X, McNamara S, et al. Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota. *Ann Am Thorac Soc* 2014;11:1049–1055.
20. Worlitzsch D, Rintelen C, Böhm K, Wollschläger B, Merkel N, et al. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. *Clin Microbiol Infect* 2009;15:454–460.
21. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, et al. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. *J Clin Microbiol* 2006;44:2601–2604.
22. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, et al. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. *J Clin Microbiol* 2006;44:2601–2604.
23. Sherrard LJ, Bell SC, Tunney MM. The role of anaerobic bacteria in the cystic fibrosis airway. *Curr Opin Pulm Med* 2016;22:637–643.
24. Sibley CD, Duan K, Fischer C, Parkins MD, Storey DG, et al. Discerning the complexity of community interactions using a *Drosophila* model of polymicrobial infections. *PLoS Pathog* 2008;4:e1000184.
25. Line L, Alhede M, Kolpen M, Kühl M, Ciofu O, et al. Physiological levels of nitrate support anoxic growth by denitrification of *Pseudomonas aeruginosa* at growth rates reported in cystic fibrosis lungs and sputum. *Front Microbiol* 2014;5:554.
26. Pallett R, Leslie LJ, Lambert PA, Milic I, Devitt A, et al. Anaerobiosis influences virulence properties of *Pseudomonas aeruginosa* cystic fibrosis isolates and the interaction with *Staphylococcus aureus*. *Sci Rep* 2019;9:6748.
27. Sherrard LJ, McGrath SJ, McIlreavey L, Hatch J, Wolfgang MC, et al. Production of extended-spectrum β -lactamases and the potential indirect pathogenic role of *Prevotella* isolates from the cystic fibrosis respiratory microbiota. *Int J Antimicrob Agents* 2016;47:140–145.
28. Keravec M, Mounier J, Guilloux C-A, Fangous M-S, Mondot S, et al. *Porphyromonas*, a potential predictive biomarker of *Pseudomonas*

- aeruginosa* pulmonary infection in cystic fibrosis. *BMJ Open Respir Res* 2019;6:e000374.
29. Bernarde C, Keravec M, Mounier J, Gouriou S, Rault G, et al. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation. *PLoS One* 2015;10:e0124124.
30. Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. *PLoS One* 2013;8:e62917.
31. Mac Aogáin M, Narayana JK, Tiew PY, Ali NABM, Yong VFL, et al. Integrative microbiomics in bronchiectasis exacerbations. *Nat Med* 2021;27:688–699.

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as 'excellent' or 'very good'.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.